.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Covington
US Army
Johnson and Johnson
Healthtrust
Chinese Patent Office
Cipla
Citi
Merck

Generated: November 22, 2017

DrugPatentWatch Database Preview

VESICARE Drug Profile

« Back to Dashboard

Which patents cover Vesicare, and when can generic versions of Vesicare launch?

Vesicare is a drug marketed by Astellas and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-two countries and six supplementary protection certificates in six countries.

The generic ingredient in VESICARE is solifenacin succinate. There are thirty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.

Summary for VESICARE

Pharmacology for VESICARE

Medical Subject Heading (MeSH) Categories for VESICARE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
VESICARE
solifenacin succinate
TABLET;ORAL021518-001Nov 19, 2004ABRXYesNo► Subscribe► SubscribeY► Subscribe
Astellas
VESICARE
solifenacin succinate
TABLET;ORAL021518-002Nov 19, 2004ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VESICARE

Drugname Dosage Strength RLD Submissiondate
solifenacin succinateTablets5 mg and 10 mgVesicare4/8/2009

Non-Orange Book Patents for Tradename: VESICARE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,174,896 Quinuclidine derivatives and medicinal composition thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VESICARE

Country Document Number Estimated Expiration
Germany122004000048► Subscribe
Denmark0801067► Subscribe
Finland115631► Subscribe
Australia4355396► Subscribe
Japan3014457► Subscribe
Finland972775► Subscribe
Poland182344► Subscribe
Netherlands300141► Subscribe
New Zealand298144► Subscribe
Norway973027► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VESICARE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0801067/01Switzerland► SubscribePRODUCT NAME: SOLIFENACIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57203 12.05.2006
C/GB04/029United Kingdom► SubscribePRODUCT NAME: SOLIFENACIN AND/OR PHARMACEUTICALLY ACTIVE SALT THEREOF; REGISTERED: NL RVG 29151 20031216; NL RVG 29152 20031216; UK PL 00166/0197 20040816; UK PL 0016/0198 20040816
133Luxembourg► Subscribe91133, EXPIRES: 20181118
2004 00037Denmark► Subscribe
C0032France► SubscribePRODUCT NAME: SUCCINATE DE SOLIFENACINE; NAT. REGISTRATION NO/DATE: NL 30 109 20040816; FIRST REGISTRATION: NL - RVG 29 151 20031216
C014/2004Ireland► SubscribeSPC014/2004: 20050803, EXPIRES: 20181215
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Cerilliant
Julphar
McKinsey
Harvard Business School
Novartis
Medtronic
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot